AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development With a grant of USD 475,000, the Michael J. Fox Base is funding preclinical advancement of a vaccine against Parkinson’s disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that may slow or quit the progression of Parkinson’s disease buy cialis generic . The basis of PD01 may be the company’s AFFITOME technology, which already delivered, amongst others, two vaccines from AFFiRiS AG for the treatment of Alzheimer’s disease. AFFiRiS AG, based in Vienna, Austria, today announced that among its current nine advancement programs will receive funding from the united states Michael J.
Offers been found to enhance the ongoing health of the mind through the advancement of ‘brain reserve,” said Paul Nussbaum, Ph.D., chairman of AFA’s Prevention Advisory Panel and a brain wellness expert whose latest book is entitled ‘SAVE YOUR VALUABLE Brain.’ Reagle and his wife, Marie Haley, of Tampa, FL have a personal interest in the cause, having been caregivers for ‘1,000 times’ for Marie’s mother, who got Alzheimer’s disease. ‘Alzheimer’s disease is usually devastating to the individuals who have it, but it’s especially tough on family caregivers, who are overworked and underfunded perennially.